Syrian Cardiovascular Association, Damascus, Syria.
Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Saarland University Medical Center, Saarland University, Saarbrücken, Germany.
ESC Heart Fail. 2022 Dec;9(6):4003-4009. doi: 10.1002/ehf2.14119. Epub 2022 Aug 23.
Lower socio-economic status may delay and even prevent the application of guideline-directed heart failure (HF) therapy for most patients. This study aims to evaluate the feasibility and possible difficulties facing the application of this treatment during the current Syrian conflict.
A questionnaire on HF management and feasibility of recommended HF therapy was addressed to physicians practising cardiology in Syria. The questionnaire consisted of 30 questions and focused on the quality of HF management and awareness of recommended drug and device therapy for HF among physicians practising cardiology in Syria. A total of 228 physicians participated in the survey. Awareness of recommended medical and device therapy of HF was very high among participants (98% and 95%, respectively). The majority of participants (>75%) believe that more than half of HF patients do not receive optimal medical HF therapy. Ninety per cent of participants believe that <10% of patients with an appropriate indication for device therapy receive it. More than 75% of participants believe that the cost of medications, alone or in combination with other medical causes, represents the major problem facing the application of optimal HF medical therapy. More than 95% of participants reported that cost alone, or in combination with unavailability, is the primary reason why patients with appropriate indications are not offered device therapy.
Despite the high level of awareness of recommended HF therapies among Syrian cardiologists, the majority of HF patients are still undertreated. Financial difficulties and lack of resources are the main causes of this problem.
较低的社会经济地位可能会延迟甚至阻止大多数患者接受指南指导的心衰(HF)治疗。本研究旨在评估在当前叙利亚冲突期间应用这种治疗的可行性和可能面临的困难。
向在叙利亚从事心脏病学工作的医生发送了一份关于 HF 管理和推荐 HF 治疗可行性的问卷。问卷共包含 30 个问题,重点关注 HF 管理的质量以及在叙利亚从事心脏病学工作的医生对推荐的 HF 药物和设备治疗的认识。共有 228 名医生参与了这项调查。参与者对推荐的 HF 药物和设备治疗的认识非常高(分别为 98%和 95%)。大多数参与者(>75%)认为,超过一半的 HF 患者未接受最佳的 HF 药物治疗。90%的参与者认为,只有不到 10%的有适当设备治疗适应证的患者接受了这种治疗。超过 75%的参与者认为,仅药物费用或与其他医疗原因相结合的费用是实施最佳 HF 药物治疗的主要问题。超过 95%的参与者报告称,仅费用或与无法获得治疗相结合是不向有适当适应证的患者提供设备治疗的主要原因。
尽管叙利亚心脏病专家对推荐的 HF 治疗方法的认识水平很高,但大多数 HF 患者仍未得到充分治疗。经济困难和资源匮乏是造成这一问题的主要原因。